Answers are grounded in this paper and cite their sources.
(2019). A targeted approach to reducing rates of discontinuation and dose reduction in patients receiving sorafenib or regorafenib. Journal of Drug Assessment: Vol. 8, Abstracts from the Seventh Annual National Association of Specialty Pharmacy (NASP) Meeting, pp. 30-30.
No takes yet. Share an insight, caveat, or question.
Nix et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: